Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 262-872-0 | CAS number: 61617-00-3
In accordance with an OECD TG 406 study conducted under GLP conditions in guinea pigs ZMB2 is considered sensitising (Safepharm, 2002).
In accordance with an OECD TG 406 study conducted under GLP conditions in guinea pigs, a positive result (50% sensitisation) was observed, therefore, ZMB2 is considered sensitizing to the skin (Safepharm, 2002). Justification for selection of skin sensitisation endpoint: Key study, conducted to GLP and appropriate OECD Guideline.
An in vitro study was not required, given the availability of adequate in vivo skin sensitisation data.
A positive result of 50% sensitisation was observed in an OECD TG 406 study with ZMB2 (Safepharm, 2002).
Therefore, in accordance with Regulation No. 1272/2008 (amended in Regulation No. 286/2011) Table 3.4.2, ZMB2 is classified as skin sensitiser Category 1B.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again